Fulvestrant is a drug treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression as well as HR-positive, HER2-negative advanced breast cancer in combination with palbociclib in women with disease progression after endocrine therapy.
It is a selective estrogen receptor degrader (SERD) and was first in class to be approved. It works by binding to the estrogen receptor and destabilizing it, causing the cell’s normal protein degradation processes to destroy it. It is given by muscle injection.
Sterling holds Certificate of Suitability n. R0-CEP 2013-031-Rev 00 issued by Quality of Medicines & HealthCare (EDQM) on 03/02/2015.
US DMF was submitted to FDA on 30/01/2013 and the following number was assigned n. 26855.
Warning: Invalid argument supplied for foreach() in /srv/users/serverpilot/apps/sterling2019/public/wp-content/themes/sterling/single.php on line 64